Royalty Pharma Sub-Manager, LLC 13F Holdings · Q2 2026
Royalty Pharma Sub-Manager, LLC reported 4 securities worth $241.92M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: CYTK (34.52%), ZBIO (25.05%), KLRA (22.36%). Among its top 25 positions this quarter: 1 new, 1 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | CYTK | CYTOKINETICS, INC | $83.5M | 34.52% | 980,392 | Hold |
| 2 | ZBIO | ZENAS BIOPHARMA, INC. | $60.6M | 25.05% | 2.4M | Hold |
| 3 | KLRA | KAILERA THERAPEUTICS | $54.1M | 22.36% | 2.5M | New |
| 4 | BHVN | BIOHAVEN LTD | $43.7M | 18.06% | 2.9M | Hold |
| 5 | BCRX | BIOCRYST PHARMACEUTICALS INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR